Squarepoint Ops LLC cut its stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 37.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 217,239 shares of the company's stock after selling 132,761 shares during the quarter. Squarepoint Ops LLC owned about 0.84% of Contineum Therapeutics worth $3,183,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of CTNM. Legal & General Group Plc increased its stake in shares of Contineum Therapeutics by 74.0% in the 4th quarter. Legal & General Group Plc now owns 3,631 shares of the company's stock worth $53,000 after acquiring an additional 1,544 shares during the last quarter. Corebridge Financial Inc. increased its stake in shares of Contineum Therapeutics by 73.1% in the 4th quarter. Corebridge Financial Inc. now owns 5,215 shares of the company's stock worth $76,000 after acquiring an additional 2,202 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Contineum Therapeutics by 90.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company's stock worth $86,000 after acquiring an additional 2,783 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Contineum Therapeutics in the 4th quarter worth $103,000. Finally, Rhumbline Advisers grew its holdings in shares of Contineum Therapeutics by 36.3% during the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company's stock worth $121,000 after purchasing an additional 2,191 shares during the period.
Contineum Therapeutics Trading Up 1.4%
Contineum Therapeutics stock traded up $0.05 during midday trading on Friday, reaching $3.62. 58,846 shares of the stock traded hands, compared to its average volume of 83,108. The company has a 50-day simple moving average of $4.57 and a two-hundred day simple moving average of $8.94. Contineum Therapeutics, Inc. has a 12-month low of $3.35 and a 12-month high of $22.00. The firm has a market cap of $93.66 million and a PE ratio of -1.84.
Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06). Equities research analysts anticipate that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. Jones Trading assumed coverage on Contineum Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $23.00 price target for the company. Robert W. Baird lowered their price target on Contineum Therapeutics from $32.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, March 7th. Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 price target on shares of Contineum Therapeutics in a report on Thursday, May 15th. Finally, Morgan Stanley lowered their price target on Contineum Therapeutics from $25.00 to $20.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Contineum Therapeutics has a consensus rating of "Buy" and an average price target of $22.50.
Check Out Our Latest Research Report on Contineum Therapeutics
About Contineum Therapeutics
(
Free Report)
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Further Reading
Before you consider Contineum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Contineum Therapeutics wasn't on the list.
While Contineum Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
